Gene · 10038
Papers2,674
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
141 to 160 of 2,674
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Leveraging PARP-1/2 to Target Distant Metastasis. | Int J Mol Sci | 2024 | 39201718 | PubTator, text mining | PubMed |
| Regulation of PARP1/2 and the tankyrases: emerging parallels. | Biochem J | 2024 | 39178157 | PubTator, text mining | PubMed |
| Identification of epigenetic modifiers essential for growth and survival of AML1/ETO-positive leukemia. | Int J Cancer | 2024 | 39146497 | PubTator, text mining | PubMed |
| Adaptive genetic mechanisms in mammalian Parp1 locus. | G3 (Bethesda) | 2024 | 39056235 | PubTator, text mining | PubMed |
| Germline Sequencing of DNA Damage Repair Genes in Two Hereditary Prostate Cancer Cohorts Reveals New Disease Risk-Associated Gene Variants. | Cancers (Basel) | 2024 | 39001544 | PubTator, text mining | PubMed |
| Apurinic/apyrimidinic endonuclease 1 has major impact in prevention of suicidal covalent DNA-protein crosslink with apurinic/apyrimidinic site in cellular extracts. | IUBMB Life | 2024 | 38963041 | PubTator, text mining | PubMed |
| Oncometabolite 2-hydroxyglutarate suppresses basal protein levels of DNA polymerase beta that enhances alkylating agent and PARG inhibition induced cytotoxicity. | DNA Repair (Amst) | 2024 | 38897003 | PubTator, text mining | PubMed |
| The dynamics and regulation of PARP1 and PARP2 in response to DNA damage and during replication. | DNA Repair (Amst) | 2024 | 38823186 | PubTator, text mining | PubMed |
| Leveraging a rationally designed veliparib-based anilide eliciting anti-leukemic effects for the design of pH-responsive polymer nanoformulation. | Eur J Med Chem | 2024 | 38776806 | PubTator, text mining | PubMed |
| Design of Selective PARP-1 Inhibitors and Antitumor Studies. | J Med Chem | 2024 | 38776379 | PubTator, text mining | PubMed |
| PAR caps the poles: a specific role for PARP2-inhibition to target the 'clustering' of extra spindle poles in cancer cells. | EBioMedicine | 2024 | 38749301 | PubTator, text mining | PubMed |
| Specific and shared biological functions of PARP2 - is PARP2 really a lil' brother of PARP1? | Expert Rev Mol Med | 2024 | 38698556 | PubTator, text mining | PubMed |
Practical Three-Component Regioselective Synthesis of Drug-Like 3-Aryl(or heteroaryl)-5,6-dihydrobenzo[h]cinnolines as Potential Non-Covalent Multi-Targeting Inhibitors To Combat Neurodegenerative Diseases. | ACS Chem Neurosci | 2024 | 38647433 | PubTator, text mining | PubMed |
| Leveraging shape screening and molecular dynamics simulations to optimize PARP1-Specific chemo/radio-potentiators for antitumor drug design. | Arch Biochem Biophys | 2024 | 38642632 | PubTator, text mining | PubMed |
| PARP inhibitors suppress tumours via centrosome error-induced senescence independent of DNA damage response. | EBioMedicine | 2024 | 38640836 | PubTator, text mining | PubMed |
| TransGEM: a molecule generation model based on Transformer with gene expression data. | Bioinformatics | 2024 | 38632084 | PubTator, text mining | PubMed |
| PARP2 promotes Break Induced Replication-mediated telomere fragility in response to replication stress. | Nat Commun | 2024 | 38565848 | PubTator, text mining | PubMed |
| Inactive Parp2 causes Tp53-dependent lethal anemia by blocking replication-associated nick ligation in erythroblasts. | bioRxiv | 2024 | 38559022 | PubTator, text mining | PubMed |
| PARP Inhibitors for Breast Cancer Treatment: A Review. | JAMA Oncol | 2024 | 38512229 | PubTator, text mining | PubMed |
| Analysis of the Association between Copy Number Variation and Ventricular Fibrillation in ST-Elevation Acute Myocardial Infarction. | Int J Mol Sci | 2024 | 38473795 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10038/papers?page=8